Aegis Acquires Diagnovus
News Jan 12, 2015
Aegis Sciences Corporation announced the acquisition of Diagnovus LLC.
“The asset acquisition of Diagnovus allows Aegis to expand our healthcare laboratory testing services,” stated Aegis Founder, Chairman and CEO Dr. David L. Black. “The delivery of patient-specific genetic information to physicians will improve management of disease and prescribing of necessary medication.”
Diagnovus has developed multiple molecular diagnostic assays, including a buccal swab test which provides insight into an individual’s response to certain medications based on genetic structure. This valuable information may increase the quality of care by reducing the time required to find the optimal course of treatment.
“As a scientist and entrepreneur, I am proud to have our team join Aegis,” stated Diagnovus President and Co-Founder Dr. James Stover. “Aegis’ reputation and client base will allow us to offer our developed molecular diagnostic testing services to a much larger patient population.”
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Unprecedented Data on Atmosphere’s Organic Chemistry GatheredNews
The MIT team, as well as some of the other research groups, developed instruments that specifically targeted these hard-to-measure organic compounds.READ MORE
Scientists Automate Key Step in Forensic Fingerprint AnalysisNews
Scientists from the NIST and Michigan State University report that they have developed an algorithm that automates a key step in the fingerprint analysis process.READ MORE